Florida Surgery & Weight Loss Center offers personalized medical weight loss consultations for eligible Plantation patients
Safety notes: Multi-year trials cited by the Alzheimer's Drug Discovery Foundation (2015) found no severe adverse events in older adults, and a 2002 trial of 162 patients reported no serious side effects in the treatment group
Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease
Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with RYBELSUS Warnings and Precautions Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS
Do not change the dose on your own, even if weight loss slows
Contact your trial team or GP promptly if you experience: Persistent or severe nausea, vomiting, or diarrhoea that prevents adequate fluid or food intake Signs of dehydration, such as dizziness, dark urine, or reduced urination Severe or persistent abdominal pain, which may rarely indicate pancreatitis a known risk with GLP-1 receptor agonist therapies or gallbladder problems [18] [21] Rapid or irregular heartbeat (palpitations) Significant injection site reactions, including signs of infection (redness, warmth, swelling, or discharge) Symptoms of low blood sugar (hypoglycaemia) if you are also taking insulin or a sulfonylurea, such as shakiness, sweating, or confusion If you are unsure whether your symptoms require urgent attention, contact NHS 111 (by phone or online at 111.nhs.uk) for advice